MyoKardia is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.Read More
Recent Press Releases
09/20/18MyoKardia Launches Inaugural MyoSeeds™ Research Grants Program to Advance Independent Research in Heart Disease
NASDAQ GS | MYOK (Common Stock)
$53.42 + 0.47
10/15/184:00 p.m. ETData provided by Nasdaq. Minimum 15 minutes delayed.
There are currently no events scheduled.